Incremental cost evaluation study: Of INR Auto-monitoring versus Laboratorial Control or Monitoring in Health Care Centres, in Portugal;Estudo de avaliação do custo incremental: Da auto-monitorização de INR versus Controlo Laboratorial ou Monitorização no Centro de Saúde, em Portugal

Acta Medica Portuguesa

Volumn 23, Issue 2, 2010, Pages 203-212

  Macedo, Ana ^a   Carrasco, João ^a   Andrade, Sofia ^a   Moital, Inês ^a  

^a Consultoria Cientifica ^*  (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CENTER; HUMAN; INTERNATIONAL NORMALIZED RATIO; MONITORING; PREDICTION; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

AMBULATORY CARE FACILITIES; COST-BENEFIT ANALYSIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LABORATORY TECHNIQUES AND PROCEDURES; MONITORING, PHYSIOLOGIC; PORTUGAL; QUALITY OF LIFE; SELF CARE;

EID: 77953393759     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. FIHN SD, MCDONEL M, MARTIN D, HENIKOFF J, VERMES D, WHIT RH: Risk factors for complications of chronic anticoagulation. A multycenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993;118(7):5111-20
2. LAFATA J, MARTIN S, KAATZ S, WARD R: The Cost-effectiveness of Different Management Strategies for Patients on Chronic Warfarin Therapy. JGIM 2000;15:31-7
3. FRITSCHI J, MULLER P, SCHMID P, WUILLEMIN W: Patiente self-mangement of long term oral anticoagulation in Switzerland. Swiss Med WKLY 2007;137:252-258.
4. REGIER D, SUNDERJI R, LYND L, GIN K, MARRA C: Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ 2006;174(13):1847-52
5. CONNOCK M, STEVENS C, FRY-SMITH A et al: Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. HTA 2007;11(38)
6. CHIQUETTE E, AMATO MG, BUSSEY HI: Comparison of anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care cost. Arch Intern Med 1998;158:1641-7
7. HASENKAN JM, KNUDSEN L, KIMOSE HH et al: Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ration (INR) using a portable whole blood monitor. A pilot investigation. Thromb Res 1997;85(1):77-82
8. GOTTLIEB LK, SALEM-SCHATZ S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154(17):1945-53
9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Eng J Med 1990;323(22):1505-11
10. PALARETI G, LEALI N, COCCHERI S et al: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423-8
11. ANSELL JE, PATEL N, OSTROVSKY D, NOZZOLILLO E, PETERSON AM, FISH L: Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155(20):2185-9
12. VAN DER MEER FJ, ROSENDALL FR, VANDENBROUCKE JP, BRIET E: Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153(13):1557-62
13. WHITE RH, MCCURDY SA, VON MARENSDORFF H, WOODRUFF DE Jr, LEFTGOFF L: Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med 1998;111(9):730-7
14. ANDERSON DR, HARRISON L, HIRSH J: Evaluation of portable prothombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch Intern Med 1993; 153(12):1441-7
15. CANNEGIETER SC, ROSENDAAL FR, WINTZEN AR et al: Optimal anticoagulant therapy in patients with mechanical heart valves. N Eng J Med 1995;333(1):11-7
16. The European Atrial Fibrillation Trial Study Group (EAFTSG): Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Eng J Med 1995; 333(1):5-10
17. TANGELDER MJ, ALGRA A, LAWSON JA, HENNEKES S, EIKELBOOM BC: Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA study Group. J Vasc Surg 2001;33(3):522-7
18. GAGE BF, CARDINALLI AB, ALBERS GW, OWENS DK: Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1996; 275(12):909
19. Direcção Geral de Saúde: Risco de morrer em Portugal 2001, Direcção de Serviços de Informação e Análise, Divisão de Epidemiologia 2003
20. HERVÁS A, CABASÉS J, FORCEN T: Coste des cuidado del Ictus en una población general n institucionalizada. Gac Sanit 2007; 21(6):444-451
21. JORGENSEN N, CABAÑAS M, OLIVA J, REJAS J, LEON T: Los costes de los cuidados informales associados a enfermedades neurológicas discapacitantes de alta prevalencia em España. Neurologia 2008;23(1):29-39